Upregulation of ErbB4 and its ligands could promote the development of BLCA, and the co-expression of ErbB3 and ErbB4 has been reported to be associated with an improved survival time in BLCA patients (Memon et al., 2004). This evidence concerns the gene ERBB3 and bladder transitional cell carcinoma.